Compare VENUS REMEDIES with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AUROBINDO PHARMA VENUS REMEDIES/
AUROBINDO PHARMA
 
P/E (TTM) x -1.2 10.0 - View Chart
P/BV x 0.1 1.8 4.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
AUROBINDO PHARMA
Mar-19
VENUS REMEDIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs126830 15.2%   
Low Rs61527 11.6%   
Sales per share (Unadj.) Rs301.8333.9 90.4%  
Earnings per share (Unadj.) Rs-24.940.4 -61.6%  
Cash flow per share (Unadj.) Rs2.551.8 4.9%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs293.3237.1 123.7%  
Shares outstanding (eoy) m12.34585.91 2.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.0 15.2%   
Avg P/E ratio x-3.816.8 -22.4%  
P/CF ratio (eoy) x36.713.1 280.3%  
Price / Book Value ratio x0.32.9 11.1%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m1,154397,569 0.3%   
No. of employees `0000.917.9 5.2%   
Total wages/salary Rs m39325,849 1.5%   
Avg. sales/employee Rs Th4,026.110,956.9 36.7%   
Avg. wages/employee Rs Th425.01,447.7 29.4%   
Avg. net profit/employee Rs Th-331.81,324.3 -25.1%   
INCOME DATA
Net Sales Rs m3,724195,636 1.9%  
Other income Rs m231,553 1.4%   
Total revenues Rs m3,747197,189 1.9%   
Gross profit Rs m39539,519 1.0%  
Depreciation Rs m3386,680 5.1%   
Interest Rs m3542,626 13.5%   
Profit before tax Rs m-27531,767 -0.9%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m327,269 0.4%   
Profit after tax Rs m-30723,645 -1.3%  
Gross profit margin %10.620.2 52.5%  
Effective tax rate %-11.522.9 -50.2%   
Net profit margin %-8.212.1 -68.2%  
BALANCE SHEET DATA
Current assets Rs m2,638153,645 1.7%   
Current liabilities Rs m2,305120,429 1.9%   
Net working cap to sales %8.917.0 52.7%  
Current ratio x1.11.3 89.7%  
Inventory Days Days135135 100.2%  
Debtors Days Days4664 72.7%  
Net fixed assets Rs m4,871103,909 4.7%   
Share capital Rs m123586 21.1%   
"Free" reserves Rs m3,496138,322 2.5%   
Net worth Rs m3,619138,908 2.6%   
Long term debt Rs m1,3741,800 76.4%   
Total assets Rs m7,509264,544 2.8%  
Interest coverage x0.213.1 1.7%   
Debt to equity ratio x0.40 2,931.5%  
Sales to assets ratio x0.50.7 67.1%   
Return on assets %0.69.9 6.4%  
Return on equity %-8.517.0 -49.8%  
Return on capital %1.623.8 6.6%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m097,316 0.0%   
Fx outflow Rs m51740,589 1.3%   
Net fx Rs m-51756,727 -0.9%   
CASH FLOW
From Operations Rs m51416,220 3.2%  
From Investments Rs m-123-28,768 0.4%  
From Financial Activity Rs m-38719,191 -2.0%  
Net Cashflow Rs m46,656 0.1%  

Share Holding

Indian Promoters % 32.9 54.1 60.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.3%  
FIIs % 0.6 27.7 2.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.2 651.0%  
Shareholders   20,121 69,601 28.9%  
Pledged promoter(s) holding % 36.4 8.6 424.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - FRESENIUS KABI ONCO. COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS